||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Summit Corp Share Discussion Threads
Showing 37951 to 37975 of 37975 messages
|Depositary Fees Notification
Bank of New York Mellon
|Agree completely Luminoso.
Winning the award for "Clinical Advance Of The Year" will surely have been a been an opportunity to talk the talk with the movers and shakers, under far more enlightening circumstances than any invitation to present in a board room? I do hope they took advantage of the occasion.|
|Just US traders taking this down to another bottom, so they can pile back in before C Diff news hits. I hope to join them at the bottom and add more, just not sure where it will be. I have freed up funds from elsewhere as a really cheap buying opp seems likely.|
|sorrento06 i agree,it is disgraceful that we get no information at all.there must be something that they can tell us to cheer us up,gl,joe.|
|I genuinely can't believe we haven't had an RNSon this share. With all the things going on, delayed CDiff, awards...|
|IMO that win deserves a 1200 RNS.|
|Used to run some awards (in a different industry) and they were great fun and made a real difference (for a short time at least) to the winning teams.
See the US bill looks to be sailing through. We might just get to enjoy the fruits of the rare disease voucher!
|However ... life is cruel and I've found that winning awards in the UK can be bad news for the long term career. (11k shares sold first thing) Here's to a long and fruitful career for both the C Diff drug and Summit! (Noises off - the sound of shares selling like hot cakes.)|
|Well done all at Summit!|
|Great stuff guys and gals ... CONGRATULATIONS SUMMIT ... and typically modest, they haven't even announced it on their Twitter feed (or perhaps too busy celebrating?!)
Wonderful ... hope all are enjoying a moment of glory.|
|Excellent news, well done Summit !!|
|They won !!!!!
Scrip @PharmaScrip 51s52 seconds ago
.@Summitplc’s Phase II CoDIFy study win #ScripAwards 2016 QuintilesIMS' Clinical Advance of the Year Award
0 replies 0 retweets 0 likes
|Summit Therapeutics @Summitplc 6m6 minutes ago
We've updated https://clinicaltrials.gov/ct2/show/NCT02858362 … w/ additional locations & contact info for PhaseOut DMD #utrophin #Duchenne|
|Summit Therapeutics @Summitplc 32m32 minutes ago
Our team is @PharmaScrip 's #ScripAwards tonight. We're shortlisted for clinical advance of the year for the Ph 2 of ridinilazole in #cdiff|
A number of measures in here that should be good for SUMM, including continuing with the voucher programme (ie the one we got), biomarkers and generally speeding up FDA, including specific mention of anti-biotics
Edit: the voucher only gets awarded if we get approvals, but has a value in itself with a number having sold for $350m a pop|
|freemoney, whoever edited the page has taken the Wainwright note as it's base. Actually it's a straight lift.|
|I've noticed the Ridinilazole Wikipedia page recently.
The commercialisation section seems to imply the deal has already been done. But obviously we would have been told officially if it had. Remember anyone can edit these pages. Either way it makes interesting reading for now and I'll be interested to see how far the official deal and numbers will differ.... hopefully we'll know shortly... GLA
"Ridinilazole is manufactured by Summit Therapeutics. Summit Therapeutics plans to partner with another pharmaceutical company to begin Phase 3 trials. They predict for both the US and EU launch to occur in 2021 with peak sales of £930 million. Summit will receive a flat 20% royalty rate. Models predict that royalties will rise from £25.6 million in FY2022 to £75.2 in FY2027. Ridinilazole has been de-risked with positive Phase 2 data.
Summit estimates that the price will be $1,200 for one course of therapy in the US and approximately 20% less in the EU. This is in contrast to Merck's Dificid (fidaxomicin) which was priced at $2,800 per course of therapy. Dificid did not sell well because it cost nearly four times as much as the generic vancomycin alternatives.
According to H.C. Wainwright, ridinilazole is currently undervalued since ridinilazole allows the patients gut microflora to be preserved which helps prevents deadly recurrent infections and allows for the use of ridinilazole as a first line therapy, in contrast with antibiotics already on the market.|
|Not seen any notice of a webcast?
Is this similar/same as Trumps idea? Could prove rather useful!|
|NASDAQ still maintaining momentum - fingers crossed.Looking forward to Tuesday's webcast by Summit (hopefully if same as last year) at:
OPPENHEIMER & COMPANY LIFE SCIENCES SUMMIT 29 November 2016, New York City, US
Edit: Notice of webcast not yet notified but expecting RNS Tuesday (i.e. expecting per last year).|
|It's surely time for an update on RDZ. Will it mirror the SRPT deal? And who knows about the shelf zombies? I noted recently the BMS were more active (not directly relevant) hTtps://endpts.com/bristol-myers-hands-over-100m-in-cash-for-a-new-fibrosis-drug-beefing-up-nash-focus/|
|liking the action on nasdaq.....|
|Amyloid hypothesis loosing traction in Alzheimer's. Focus back on Tau
Interesting .... Summit|
|Morning Sorrento ... it's "the day after thanksgiving" and a Public Holiday in the USA, so highly unlikely. But there must be news soon. Meanwhile a huge opportunity to buy shares at a ridiculous Black Friday discount!|
|Is today the day for C diff?|
|Chris, they could have been buys at yesterdays trading range.... and I suspect they were since the price moved up. Buy 'em cheap while you still can :-)|